Interethnic Differences in Bladder Cancer Incidence and the Association between Type 2 Diabetes and Bladder Cancer in the Multiethnic Cohort Study.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
29
07
2022
revised:
11
11
2022
accepted:
04
04
2023
medline:
30
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Research on the association between type 2 diabetes (T2D) and bladder cancer (BCA) risk among non-European ancestry populations is sparse to nonexistent, and most prior studies rely on a single baseline assessment of T2D status. We estimated the T2D-BCA association using the Multiethnic Cohort Study of 185,059 men and women in California and Hawaii. Participants were African American, European American, Japanese American, Latin American, and Native Hawaiian, ages 45-75 years at enrollment (1993-1996). T2D was assessed by self-report at baseline, follow-up surveys, and Medicare claims. Cases were identified using Surveillance, Epidemiology and End Results Program cancer registries through 2016. Associations were estimated by race/ethnicity using Cox proportional hazards regression. Adjusted attributable fractions (AAF) and cumulative absolute risk of bladder cancer were estimated across groups. Over an average 19.7 years of follow-up 1,890 incident bladder cancer cases were diagnosed. Time-varying T2D was associated with bladder cancer in the multiethnic sample (HR = 1.17; 95% confidence interval, 1.05-1.30); however, the HR did not differ by race/ethnicity ( T2D is significantly associated with bladder cancer risk in a multiethnic sample. Those with T2D have higher incidence of bladder cancer, regardless of racial/ethnic group. Reducing T2D prevalence could substantially lower bladder cancer incidence among Native Hawaiians due to T2D being more common in this group. High absolute risk of bladder cancer among European Americans, regardless of T2D status, indicates that elevated bladder cancer risk in this group may be due to factors other than T2D. Future studies must explore reasons for this difference in incidence.
Sections du résumé
Background
Research on the association between type 2 diabetes (T2D) and bladder cancer (BCA) risk among non-European ancestry populations is sparse to nonexistent, and most prior studies rely on a single baseline assessment of T2D status.
Methods
We estimated the T2D-BCA association using the Multiethnic Cohort Study of 185,059 men and women in California and Hawaii. Participants were African American, European American, Japanese American, Latin American, and Native Hawaiian, ages 45-75 years at enrollment (1993-1996). T2D was assessed by self-report at baseline, follow-up surveys, and Medicare claims. Cases were identified using Surveillance, Epidemiology and End Results Program cancer registries through 2016. Associations were estimated by race/ethnicity using Cox proportional hazards regression. Adjusted attributable fractions (AAF) and cumulative absolute risk of bladder cancer were estimated across groups.
Results
Over an average 19.7 years of follow-up 1,890 incident bladder cancer cases were diagnosed. Time-varying T2D was associated with bladder cancer in the multiethnic sample (HR = 1.17; 95% confidence interval, 1.05-1.30); however, the HR did not differ by race/ethnicity (
Conclusion
T2D is significantly associated with bladder cancer risk in a multiethnic sample.
Significance
Those with T2D have higher incidence of bladder cancer, regardless of racial/ethnic group. Reducing T2D prevalence could substantially lower bladder cancer incidence among Native Hawaiians due to T2D being more common in this group. High absolute risk of bladder cancer among European Americans, regardless of T2D status, indicates that elevated bladder cancer risk in this group may be due to factors other than T2D. Future studies must explore reasons for this difference in incidence.
Identifiants
pubmed: 37377897
doi: 10.1158/2767-9764.CRC-22-0288
pii: CRC-22-0288
pmc: PMC10153456
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-762Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
JAMA. 2015 Sep 8;314(10):1021-9
pubmed: 26348752
Diabetes Technol Ther. 2013 Nov;15(11):914-22
pubmed: 24180357
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
JAMA. 2021 Jun 25;:
pubmed: 34170288
Medicine (Baltimore). 2017 Nov;96(46):e8588
pubmed: 29145273
Sci Rep. 2018 Aug 21;8(1):12521
pubmed: 30131523
Cancer Epidemiol. 2011 Dec;35(6):551-4
pubmed: 21470936
Diabetologia. 2006 Dec;49(12):2819-23
pubmed: 17021919
Front Endocrinol (Lausanne). 2022 Feb 11;13:800995
pubmed: 35222270
Cells. 2020 Jun 02;9(6):
pubmed: 32498358
Diabetologia. 2014 Nov;57(11):2261-9
pubmed: 25208757
Eur J Epidemiol. 2016 Jun;31(6):575-82
pubmed: 26992709
Epidemiology. 2012 Jul;23(4):565-73
pubmed: 22517300
Biometrika. 2010 Sep;97(3):713-726
pubmed: 23956459
Int J Cancer. 2011 Feb 1;128(3):635-43
pubmed: 20473855
Am J Epidemiol. 1997 Jan 1;145(1):72-80
pubmed: 8982025
J Transl Med. 2020 Mar 30;18(1):145
pubmed: 32228610
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
Am J Epidemiol. 2015 Jun 1;181(11):917-9
pubmed: 25841869
Cancer Manag Res. 2018 Nov 26;10:6263-6274
pubmed: 30568489